TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02195921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single point Zhongwan(CV12) plus antiemetic drug
Description: All participants were supine in the hospital bed. A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1 cm above the CV12 acupoints of the stimulation point, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single point Zusanli(ST36) plus antiemetic drug
Description: A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1cm below ST36 acupoints of the stimulation point, respectively, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zusanli(ST36)and Zhongwan(CV12) plus antiemetic drug
Description: Stimulating both Zusanli(ST36)and Zhongwan(CV12)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: only antiemetic drug
Description: received routine antiemetic treatment
Study: NCT02014194

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attentional bias modification treatment
Description: The attentional bias modification treatment is a behavioral computerized program (software e-prime)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: attentional bias modification treatment
Description: The attentional bias modification treatment is a behavioral computerized program (software e-prime)
Study: NCT01035112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT02591602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleradiology Service
Description: Teleradiology Service at home or in nursing homes
Study: NCT03058081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow nasal cannula
Description: High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (\< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher\&Paykel)
Study: NCT01965431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: Medium dose oral administration
Study: NCT01874834

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ozone
Description: Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone
Description: Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone
Description: Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
Study: NCT00537446

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive positive pressure ventilation
Description: Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive positive pressure ventilation
Description: Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
Study: NCT00280566

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone Oral Capsule
Description: Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
Study: NCT01502644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Daily dosage up to 120 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Daily dosage up to 120 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Daily dosage up to 120 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Daily dosage up to 90 mg immediate release or 180 mg extended release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Daily dosage up to 90 mg immediate release or 180 mg extended release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Daily dosage up to 90 mg immediate release or 180 mg extended release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo-matching oxycodone, placebo-matching morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo-matching oxycodone, placebo-matching morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo-matching oxycodone, placebo-matching morphine
Study: NCT02827058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G25 pencil point needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G27 pencil point needle
Study: NCT02617316

Intervention type: OTHER
Group type: OTHER
Intervention: Barefoot
Description: barefoot running test was 20 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Barefoot
Description: barefoot running test was 20 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: In shoes
Description: In shoes test was 20 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: In shoes
Description: In shoes test was 20 minutes.
Study: NCT00057746

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic cranial irradiation, 2.5 Gy fx
Description: Prophylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation, 2.0 Gy fx
Description: Prophylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation, 1.5 Gy fx
Description: Prophylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy
Study: NCT03065556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 188-0551 Solution
Description: Topical solution containing active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Description: Topical solution containing no active drug
Study: NCT02002234

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hemicraniotomy
Description: Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard medical treatment
Description: Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
Study: NCT01721590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongxinluo
Description: Tongxinluo,3 capsules/time 3times/day for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 capsules/time，3times/day for 1 year
Study: NCT04090567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT02277496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Toolkit Intervention
Description: The toolkit intervention consists of strategies and activities to engage students (student toolkit) and school wellness councils (school toolkit) in addressing the six targeted behaviors of the 2010 Dietary Guidelines based on the principles of participatory action research. The intervention will promote goal setting and school-based food and physical promotion activities led by students as well as school wellness network development.
Study: NCT00393939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Description: Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
Study: NCT05611086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: Subjects in treatment group will be given capsules containing 600 mg of NAC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects in the control group will be given capsules containing placebo (lactose)
Study: NCT00748956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose NPY
Description: 50nmol, administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose NPY
Description: 100nmol administered intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator (0nmol)) administered intranasally
Study: NCT01539382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebral oxygenation intervention
Description: The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow \>2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
Study: NCT00449293

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard cognitive behavioral therapy
Description: Standard therapy to help participants with smoking cessation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy
Description: A novel mind body therapy that extends basic CT principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
Study: NCT01606085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HF DM self care
Description: Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
Study: NCT04542070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Tablets
Description: CAB tablets were available as film coated tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injectable Suspension (CAB LA)
Description: CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir Injectable Suspension (CAB LA)
Description: CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Tablets
Description: RPV was administered as tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Injectable Suspension (RPV LA)
Description: RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilpivirine Injectable Suspension (RPV LA)
Description: RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIKTARVY Tablets (BIK)
Description: BIK was a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
Study: NCT02510846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive educative management
Description: 5 hours a week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive educative management
Description: 5 hours a week
Study: NCT02988063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol Endovenous Microfoam (PEM)
Description: Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
Study: NCT03917134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cephalosporin + Metronidazole Vaginal
Description: administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cephalosporin + Placebos
Description: administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
Study: NCT00961324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
Study: NCT04463381

Intervention type: PROCEDURE
Intervention: choledochotomy techniques during LCBDE

Intervention type: PROCEDURE
Intervention: choledochotomy techniques during LCBDE

Intervention type: PROCEDURE
Intervention: choledochotomy techniques during LCBDE
Study: NCT03244228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Concentrate
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Concentrate
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Concentrate
Description: Matching placebo
Study: NCT00808938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MST
Description: Magnetic Seizure Therapy
Study: NCT04631497

Intervention type: DIAGNOSTIC_TEST
Intervention: test
Description: 1. Beck's Test~2. Test STAI~3. Test PSS~4. the scale of the fascination with death~5. COPE
Study: NCT00647192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 50 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg per day
Study: NCT01234623

Intervention type: OTHER
Intervention: UCS eyedrops
Description: 1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days
Study: NCT03697200

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APA
Description: Light touch using vaccaria seeds on specific points of the ear

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham APA control
Description: Light touch using vaccaria seeds on different points of the ear (compared to the APA group).

Intervention type: OTHER
Group type: OTHER
Intervention: Education control
Description: Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Materials will be tailored so that they can be delivered within 15 minutes for each session
Study: NCT04612634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun
Description: Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun. 0.5ml per dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang
Description: Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang. 0.5ml per dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS
Description: Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml per dose.
Study: NCT04961892

Intervention type: PROCEDURE
Intervention: surgical treatment
Description: Anatomical contraction and termination reconstruction of the lateral ligament

Intervention type: PROCEDURE
Intervention: conservative treatment
Description: Rehabilitation intervention training
Study: NCT02985242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin placebo
Description: Placebo tablet manufactured to mimic Empagliflozin 25 mg film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride placebo
Description: Placebo tablet manufactured to mimic Glimepiride 2 mg tablet
Study: NCT00627679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Inhalation Suspension
Description: Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Inhalation Suspension
Description: Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Inhalation Suspension
Description: Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Study: NCT01965431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 placebo
Study: NCT00627679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Inhalation Suspension
Description: Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Study: NCT01965431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Description: Medium dose oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin (Avalox®)